Introduction: Why Research and Development Relief Can Cost You Money
Research and development relief rewards innovation in Britain, yet it can quietly raise the tax bill of the American who owns the company. Furthermore, the damage happens invisibly, inside a computation most owners never inspect. Consequently, a relief designed to return cash to your business can hand a slice of it to the IRS instead.
The research and development relief mechanism is simple once you see it. Specifically, Britain lets a credit wipe out your corporation tax, and America then refuses to credit tax you never actually paid. Therefore, the very success of your claim shrinks the relief available on your American return.
Our clients rarely model this before filing. Additionally, their UK accountants optimise the British position in isolation, because that is the engagement they were given. Meanwhile, nobody runs the second computation. Hence, the money leaks.
Why Research and Development Relief Behaves Differently Across Two Systems
Britain treats the credit as a subsidy delivered through the tax system. In contrast, America asks a narrower question: how much foreign income tax did you genuinely pay? Those two framings diverge sharply whenever a credit discharges a liability rather than reducing profit.
That research and development relief divergence is not a loophole or a grey area. Rather, it follows directly from the American rules on what counts as a creditable foreign tax. Accordingly, the outcome is predictable, and you can plan around it if you model both countries before you claim.
Who This Guide Is Written For
This guide to research and development relief addresses the American who owns or controls a British trading company. Notably, that includes founders, investors and executives holding shares in UK software, engineering, biotech and manufacturing businesses.
We wrote it for owners rather than for corporate tax departments. Moreover, individual shareholders suffer this problem far more severely than large multinational parents, for reasons we set out below. Therefore, the smaller and more entrepreneurial your structure, the more this matters.
How Research and Development Relief Works in Britain
Britain rebuilt research and development relief in 2024. Specifically, the old SME scheme and the large-company scheme collapsed into a single credit for accounting periods beginning on or after 1 April 2024. Consequently, almost every claimant now uses one of two routes.
How Research and Development Relief Delivers Twenty Per Cent
The merged scheme delivers a taxable expenditure credit worth twenty per cent of qualifying costs. Critically, the credit counts as income, so corporation tax applies to it. Therefore, a company paying the twenty-five per cent main rate keeps a net benefit of roughly fifteen per cent of qualifying spend.
That "above the line" treatment matters commercially. Furthermore, the credit appears in your profit and loss account rather than buried in the tax charge, which investors and lenders can see. Additionally, loss-making companies under the merged scheme retain a net benefit of about 16.2 per cent.
The HMRC guidance on the expenditure credit sets out the statutory route. Meanwhile, the underlying law now sits in Part 3 Chapter 6A of the Corporation Tax Act 2009.
The Seven Steps and the PAYE Cap
Research and development relief passes through a seven-step calculation before any cash reaches you. Importantly, the first steps use the credit to discharge your corporation tax liability, and only the remainder can be paid out. That sequencing is the exact feature that damages the American position.
A cap also limits the payable element. Specifically, the payable amount cannot exceed £20,000 plus three times your PAYE and employee Class 1 National Insurance liabilities. Consequently, companies with contractor-heavy teams and thin payrolls often receive less cash than they expect.
Notional tax restrictions apply at earlier steps too. Therefore, the headline twenty per cent rarely equals the cash that lands in your account.
Enhanced Support for R&D-Intensive Companies
Loss-making SMEs that spend heavily on innovation use a different route. Specifically, Enhanced R&D Intensive Support gives an additional 86 per cent deduction, producing a total deduction of 186 per cent of qualifying expenditure.
Those companies may then surrender losses for a payable credit at 14.5 per cent. However, the route opens only where qualifying expenditure reaches at least thirty per cent of total expenditure, measured for periods beginning on or after 1 April 2024. Additionally, the company must be a genuine SME. That means fewer than 500 employees, plus either turnover under €100 million or a balance sheet under €86 million.
The intensity test catches people out. For instance, a single large non-R&D cost late in the year can drop you under thirty per cent and remove the route entirely.
What Qualifies for Research and Development Relief After 2024
Qualification for research and development relief narrowed considerably alongside the merger. Moreover, the restrictions bite hardest on exactly the cross-border structures American owners tend to build.
The Overseas Expenditure Restriction
Since April 2024, the work must generally happen in the United Kingdom. Specifically, the activity must be physically located in the UK, or performed by individuals subject to UK payroll taxes. Consequently, a British company that runs its development team from the United States usually cannot claim for that spend.
A narrow exception survives for qualifying overseas expenditure. However, it demands conditions unavailable in Britain that would be wholly unreasonable to replicate here. Geography, population and regulatory environment can all count. Notably, cost and workforce availability do not count as such conditions.
American founders frequently discover this too late. Therefore, if you moved engineering to a US or Indian team for commercial reasons, expect your qualifying base to shrink sharply.
Contracted-Out Work and Who Owns the Claim
Only one company can claim research and development relief for a given piece of work. Specifically, the claim belongs to the company that decided to carry out the research, not necessarily the one that performed it. Consequently, group structures must decide deliberately where the claim sits.
Several exceptions redirect the claim upstream. For example, the rules address ineligible customers and group elections. They also cover work the parties expected to subcontract, and in-house research unconnected to any customer contract. Guidance in the Corporate Intangibles Research and Development Manual works through the detail.
Cross-border contracting adds a further layer. Furthermore, where a US parent commissions the work, the British subsidiary may lose the claim it assumed it held.
Subcontractors and Externally Provided Workers
Payments to unconnected subcontractors qualify at sixty-five per cent of the cost. Meanwhile, connected-party arrangements follow different rules and require careful documentation of actual costs incurred.
Externally provided workers follow the same broad pattern. Therefore, agency-supplied engineers need contracts and records that prove the relationship, the location of the work, and the payroll treatment. Above all, keep the evidence contemporaneous rather than reconstructing it during an enquiry.
The Claim Process and the Deadlines That Void a Claim
Process failures now destroy more research and development relief claims than technical arguments do. Additionally, two administrative steps carry absolute deadlines, and missing either invalidates the claim completely.
The Research and Development Relief Notification Trap
New claimants must notify HMRC in advance. Specifically, the claim notification must arrive within six months of the end of the accounting period to which the claim relates. Consequently, a company with a 31 December 2025 year end had until 30 June 2026 to notify.
The requirement applies where the company has not claimed in any of the three previous accounting periods. Therefore, a business returning to innovation after a gap is treated as a new claimant. Notably, no reasonable-excuse relief rescues a late notification, so the entire year is lost.
American owners miss this constantly. Furthermore, the deadline runs from the accounting period end rather than the filing date, which sits far earlier than most owners assume.
The Additional Information Form
Every claim also requires an Additional Information Form. Specifically, HMRC has required it for all claims since 8 August 2023, submitted before or alongside the company tax return. Consequently, a claim filed without a prior form is invalid and HMRC will simply remove it.
The form demands project descriptions, cost breakdowns and a named senior officer. Moreover, HMRC guidance on submitting detailed information confirms the sequencing, and the claim mechanics on the company tax return follow separately.
One in Five Claims Now Faces an Enquiry
Scrutiny of research and development relief has intensified dramatically. Specifically, HMRC now opens enquiries into roughly one claim in five, and an enquiry can begin even after the money has arrived. Therefore, treat repayment as provisional rather than final.
Companies that over-claimed have a disclosure route. Additionally, HMRC publishes a process to tell HMRC if you have claimed too much, which usually produces a better outcome than waiting for discovery.
For an American owner, an enquiry carries a second cost. Consequently, any adjustment to the UK figures forces a corresponding correction to the US return filed for the same period.
Where Research and Development Relief Meets the American System
Here the mainstream research and development relief guidance stops. Every substantial UK page we reviewed explains the British mechanics thoroughly and mentions American tax not once. That silence is where the money disappears.
Why a Discharged Liability Is Not a Tax You Paid
American law credits foreign income tax that you actually paid or accrued. Critically, Treasury Regulation section 1.901-2(e) excludes amounts reasonably certain to be refunded, credited, rebated, abated or forgiven.
The 2022 final foreign tax credit regulations sharpened this considerably. Specifically, the Treasury guidance published in January 2022 tightened the compulsory payment analysis, and the practical effect is stark. Where a credit discharges your corporation tax rather than cash leaving the company, that discharged portion is not a foreign tax paid.
Consider what the seven-step mechanism does. Because the expenditure credit first extinguishes the corporation tax liability, the company writes a much smaller cheque to HMRC. Therefore, your creditable foreign tax falls to the cash actually remitted, not the gross liability shown in the computation.
Many advisers state loosely that the credit "does not wash out" the American benefit. However, that comfort applies to a corporate group with excess credits and an entirely different profile. Ultimately, for a founder-owned company the discharged portion is simply gone.
The Credit Also Inflates Your Tested Income
A second research and development relief effect compounds the first. Specifically, because the expenditure credit counts as taxable income in Britain, it increases the UK company profits that feed the American calculation of net CFC tested income.
So the credit hurts twice. Furthermore, it raises the income America measures while simultaneously cutting the foreign tax available to offset the resulting charge. Consequently, both sides of the fraction move against you at once.
The effective rate consequence follows immediately. Because cash tax collapses while measured profits rise, the effective foreign rate can fall into low single figures. Therefore, the high-tax exclusion that would otherwise shelter a normally taxed British company becomes unavailable.
Individual Owners Fare Worse Than Corporate Parents
A US corporate parent absorbs the research and development relief problem reasonably well. Specifically, it claims deemed-paid credits and currently retains ninety per cent of them against the tested income charge. Consequently, the damage is real but partially cushioned.
An individual American shareholder has no such cushion. Notably, individuals receive no deemed-paid credit at all unless they make a section 962 election, and without it the inclusion is taxed at ordinary rates. Therefore, the founder holding shares personally suffers the full impact.
That asymmetry explains why this problem is invisible in mainstream commentary. Meanwhile, the firms writing about UK innovation incentives serve corporate groups, not American individuals who happen to own British companies. Our cross-border planning service exists precisely for that gap.
Getting the Arithmetic Right on Your American Return
Accurate research and development relief reporting demands splitting a single British number into two American ones. Additionally, the split must be documented, because it will not appear anywhere on your UK filings.
Separating the Discharged Portion From the Cash Paid
Start from the corporation tax computation rather than the accounts when reporting research and development relief. Specifically, identify the gross liability, the amount the expenditure credit discharged, and the cash actually paid to HMRC. Therefore, only the third figure supports a credit claim.
Report the result consistently. Furthermore, the Form 1116 instructions and Publication 514 both require that you reduce foreign taxes by amounts you did not ultimately bear. Additionally, the IRS foreign tax credit guidance restates the same principle in plainer terms.
Keep the working papers. Consequently, if HMRC later adjusts the claim, you can retrace the American position without rebuilding it from scratch.
When a Repayable Credit Arrives
Cash research and development relief credits raise a timing question. Specifically, where the company receives a payable amount rather than merely discharging liability, no British tax was paid on that slice at all.
Later adjustments then force a redetermination. Moreover, where a foreign tax you already claimed is refunded or reduced, American law requires you to notify the change rather than quietly absorb it. Therefore, an HMRC enquiry that claws back relief creates an affirmative American filing obligation.
Our tax treaty optimisation work frequently turns on exactly these sequencing questions. Ultimately, getting the order right prevents amending the same return twice.
Missed Filings That Travel With the Claim
Ownership of a British company claiming research and development relief brings its own reporting. Specifically, an American owner must file Form 5471 annually, with penalties starting at $10,000 per company per year. Additionally, the tested income calculation is reported on Form 8992.
Company bank accounts matter too. Furthermore, where you hold signature authority over the British company accounts, foreign account reporting can apply personally, which our FBAR and FATCA service addresses directly.
We usually find these failures clustered. Therefore, an owner who never modelled the credit has often missed the information returns too. Both need correcting together on the US tax returns for the affected years.
A Worked Example: The Cambridge Software Company
Numbers make the research and development relief problem concrete. Accordingly, the following case reflects a pattern we see repeatedly among American founders in Britain.
The Facts
An American citizen living in London owns all the shares in a Cambridge software company. For the year to 31 March 2026, the company earns trading profits of £900,000 before any claim. Meanwhile, qualifying expenditure reaches £1,200,000, all of it incurred in the United Kingdom.
The company claims the merged scheme credit at twenty per cent. Therefore, the expenditure credit comes to £240,000.
The British Outcome
Because the credit is taxable, it joins the profits. Consequently, taxable profits rise to £1,140,000, and corporation tax at twenty-five per cent produces a gross liability of £285,000.
The seven-step mechanism then applies the credit against that liability. Therefore, £240,000 discharges the corporation tax, and the company pays just £45,000 in cash. Britain sees this as a straightforward success, and on British measures it plainly is.
Without any claim, the company would have paid £225,000. Accordingly, the headline British saving looks like £180,000.
The American Outcome
America now asks a different question. Specifically, the creditable foreign tax is the £45,000 actually paid, not the £285,000 computed, because the credit discharged the balance.
The effective foreign rate therefore collapses to roughly 3.9 per cent of measured profits. Consequently, the company falls far below the high-tax threshold, and the shelter that would ordinarily apply to a British company taxed at twenty-five per cent disappears entirely.
Our client made a section 962 election to access corporate rates and deemed-paid credits. Even so, the American charge came to approximately £103,000. Therefore, the genuine net benefit of the claim was around £77,000, not the £180,000 the British computation advertised.
Nothing here was wrong or aggressive. Rather, the claim was correct and fully compliant. Ultimately, the owner simply lost 57 per cent of the benefit because nobody modelled the second country before filing.
Practical Steps Before You Claim Research and Development Relief
You can keep most of the value of research and development relief with planning. Moreover, none of the steps below require unusual structures or aggressive positions.
Model Both Countries Before Filing
Run the American computation before the claim goes in, not after. Specifically, compare the cash saved in Britain against the additional charge created in America, then decide.
Sometimes the answer is to claim a smaller amount of research and development relief. Alternatively, holding the shares through a US corporation changes the analysis materially, because corporate shareholders retain deemed-paid credits.
Watch the Effective Rate Every Year
The effective foreign rate drives everything. Therefore, track it annually rather than assuming last year's conclusion still holds. Additionally, a single large claim can flip a comfortably taxed company into exposure for that year alone.
Timing offers genuine flexibility. For instance, the period in which expenditure falls can shift the rate across the threshold.
Sequence the Filings Correctly
Always settle the British position first. Consequently, you then build the American return on figures that will not move. Reversing that order guarantees an amendment.
Guidance from the ICAEW on research and development, the Chartered Institute of Taxation and the AICPA all reward reading before you commit. Meanwhile, HMRC and the IRS international business pages set out each side separately.
How TaxYork Can Help
TaxYork models both jurisdictions before a claim is filed. Furthermore, we quantify the American cost of the British credit, then advise on whether the claim, the timing or the holding structure should change.
We also repair historic positions. Specifically, where an owner claimed research and development relief and over-claimed the resulting foreign tax credit, we recompute the creditable amount, amend the affected returns and bring the information filings back into order.
Our clients are founders, investors and company owners with substantial cross-border interests. Therefore, we work at the level of detail such holdings demand, from a single annual computation through to full historic reconstruction.
Conclusion
Research and development relief remains genuinely valuable to a British company. However, its value to an American owner is materially lower than the British computation suggests, and the gap is systematic rather than occasional.
The cause is structural. Because Britain delivers the benefit by discharging a tax liability, America declines to credit tax that never left the company. Consequently, the effective foreign rate collapses, the shelter disappears, and the individual shareholder absorbs the difference.
Model both systems before you claim. Ultimately, owners who run the second computation keep most of the benefit, while those who file blind routinely surrender half of it.
Contact Us
Speak to our specialists before your next claim rather than after it. Furthermore, we can review prior years where research and development relief was claimed and quantify any exposure on your American returns.
Email hello@taxyork.com or call 020 3488 8606. Alternatively, book a consultation and we will assess your position within one working day.
Disclaimer
This article provides general information about research and development relief and the related United States reporting consequences. It does not constitute tax advice for any specific person, company or transaction. Tax rules change frequently, and their application depends entirely on individual circumstances. Therefore, you should obtain professional advice before acting. TaxYork accepts no liability for decisions taken solely on the basis of this article.